Findings

What do systematic reviews say?

4,918 questions · 5,537 findings · 1,803 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Prefabricated foot orthoses vs shoes

Serious adverse events · children with symptomatic flat feet

The review found no eligible studies for this question.

1 finding from 1 review

Foot orthoses for treating paediatric flat feet 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Custom foot orthoses vs shoes

Serious adverse events · children with asymptomatic flat feet

The review found no eligible studies for this question.

1 finding from 1 review

Foot orthoses for treating paediatric flat feet 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Naloxone vs placebo

Serious adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Lower‐dose methylnaltrexone vs higher dose

Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pyronaridine‐artesunate (PY‐AS) vs other antimalarials

Serious adverse events · adults and children with uncomplicated malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events compared with other antimalarials (moderate certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1.24 [0.54, 2.84]
7 studies · 3941 participants
Moderate

Tacrolimus vs beclometasone

Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
RR 3 [0.13, 71.7]
1 study · 88 participants
Low

Tacrolimus vs placebo

Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
RR 2.44 [0.12, 48.77]
3 studies · 148 participants
Very low

Tacrolimus vs ciclosporin

Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ceftriaxone vs azithromycin

Serious adverse events · children under 18 years of age with enteric fever

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ceftriaxone vs fluoroquinolones

Serious adverse events · adults and children with enteric fever

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cefixime vs fluoroquinolones

Serious adverse events · adults and children with enteric fever

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab intravenous (IV) vs placebo

Serious adverse events · people with asthma

Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.59 [0.37, 0.94]
3 studies · 751 participants
High

Reslizumab intravenous (IV) vs placebo

Serious adverse events · people with asthma

Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.79 [0.56, 1.12]
4 studies · 1656 participants
High

Reslizumab subcutaneous (SC) vs placebo

Serious adverse events · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.97 [0.53, 1.79]
1 study · 464 participants
High

Benralizumab subcutaneous (SC) vs placebo

Serious adverse events · people with asthma

Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.76 [0.62, 0.93]
5 studies · 3304 participants
High

Mepolizumab subcutaneous (SC) vs placebo

Serious adverse events · people with asthma

Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.68 [0.46, 1.01]
3 studies · 1231 participants
High

Autologous myeloablative selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.43 [0.99, 2.08]
1 study · 71 participants
Moderate

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.7 [1.2, 2.3]
1 study · 156 participants
Moderate

Music intervention plus standard care vs active intervention plus standard care

Serious adverse events · people with substance use disorders

The review found no eligible studies for this question.

1 finding from 1 review

Music therapy for people with substance use disorders 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found